Fcγ receptors as regulators of immune responses
The DOI matches its Crossref record; 138 of the 139 references it cites were found in a registry or an index.
Abstract
In addition to their role in binding antigen, antibodies can regulate immune responses through interacting with Fc receptors (FcRs). In recent years, significant progress has been made in understanding the mechanisms that regulate the activity of IgG antibodies in vivo. In this Review, we discuss recent studies addressing the multifaceted roles of FcRs for IgG (FcgammaRs) in the immune system and how this knowledge could be translated into novel therapeutic strategies to treat human autoimmune, infectious or malignant diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FcγR activation induces macrophage phagocytosis.44”
From Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling (2023) · cites this paper as [44]
Citations
Cites
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo
Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M., & Nussenzweig, M. C. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.769 · Cited by 1,848
Self-citationShields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754 · cited 1×
“Evidence that this sugar residue is involved in immune regulatory processes was obtained by studying the mechanism of the anti-inflammatory activity of IVIG therap”
BackgroundSelf-citationDifferential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307 · cited 1×
“This sugar side chain consists of a conserved biantennary heptasaccharide core structure containing mannose and N-acetylglucosamine (GlcNac) with varying additions of terminal and branching residues such as fucose, GlcNac, galactose and sialic aci”
BackgroundWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Several studies of lymphoma patients who had received Rituximab, a B-cell depleting chimeric IgG1 antibody that is specific for CD20, revealed that those patients with activating FcγR alleles that had a higher binding affinity for the Fc fragment of the therapeutic antibody displayed significantly improved clinical re…”
Background
Cited by
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
“Such complexes may also activate the complement system and lead to further unwanted inflammation 141 .”
BackgroundA single-cell atlas of the peripheral immune response in patients with severe COVID-19
Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martínez-Colón, G. J., McKechnie, J. L., Ivison, G. T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0944-y · Cited by 1,493
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
“In mice, ADCC is regulated predominantly by the low-affinity receptors FcRIII and FcRIV (Nimmerjahn et al., 2005; Nimmerjahn et al., 2010; Setiady et al., 2010), and to a lesser extent by the highaffinity FcRI (Fossati-Jimack et al., 2000; Tedder et al., 2006; Hamaguchi et al., 2006).”
BackgroundInfluentialSelf-citationControlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Long, E. O., Sik Kim, H., Liu, D., Peterson, M. E., & Rajagopalan, S. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075005 · Cited by 1,217
“The concept and existence of the ITIM was first established with FcγRIIb, which inhibits B cell receptor signaling by recruiting the inositol phosphatase SHIP when coligated through binding of IgG immune complexes (150, 152).”
BackgroundWiner, D. A., Winer, S., Shen, L., Wadia, P. P., Yantha, J., Paltser, G., Tsui, H., Wu, P., Davidson, M. G., Alonso, M. N., et al. (2011) · Nature Medicine · doi:10.1038/nm.2353 · Cited by 1,050
The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis
Hirayama, D., Iida, T., & Nakase, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010092 · Cited by 927
“For instance, immunoglobulin G (IgG), when specifically bound to microbial surface antigens, associates with fragment crystallizable γ receptors (FcγRs) in phagocytes, which recognizes their fragment crystallizable (Fc) region [15,16].”
BackgroundPhagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y.-X., & Weissman, I. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0183-z · Cited by 911
Monoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
“NK cells are the main effector type that mediate ADCC; however other myeloid types such as monocytes, macrophages, neutrophils, eosinophils, and dendritic cells are also capable [26].”
BackgroundGlycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
“These effector ligands include three structurally homologous cellular Fc receptor types (FcγRI, FcγRII and FcγRIII), the C1q component of complement and the neonatal Fc receptor (FcRn”
BackgroundIntravenous immunoglobulin therapy: how does IgG modulate the immune system?
Schwab, I., & Nimmerjahn, F. (2013) · Nature Reviews Immunology · doi:10.1038/nri3401 · Cited by 820
Self-citationPharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Fu, Y., Cheng, Y., & Wu, Y. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00207-4 · Cited by 788
Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
DiLillo, D. J., Tan, G. S., Palese, P., & Ravetch, J. V. (2014) · Nature Medicine · doi:10.1038/nm.3443 · Cited by 749
Self-citationRole of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
The function of Fcγ receptors in dendritic cells and macrophages
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014) · Nature Reviews Immunology · doi:10.1038/nri3582 · Cited by 639
From Vaccines to Memory and Back
Sallusto, F., Lanzavecchia, A., Araki, K., & Ahmed, R. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.008 · Cited by 637
“The B cell system is also under homeostatic control and there are mechanisms for regulating naïve and memory B cell numbers as well as total immunoglobulin levels in the serum (Nimmerjahn and Ravetch, 2008; Sanz et al., 2008).”
Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601
FcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis
Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., Korets, L., Lam, J., Tawfik, D., DeNardo, D. G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.019 · Cited by 590
“Four classes of IgG receptor FcγRs have been identified, FcγRI/CD64, FcγRII/CD32, FcγRIII/CD16, and FcγRIV, differing by their distinct affinity for IgG isotypes, cellular distributions, and effector functions (Nimmerjahn and Ravetch, 2008).”
InfluentialMouse and human FcR effector functions
Bruhns, P., & Jönsson, F. (2015) · Immunological Reviews · doi:10.1111/imr.12350 · Cited by 579
A Functional Role for Antibodies in Tuberculosis
Lu, L. L., Chung, A. W., Rosebrock, T. R., Ghebremichael, M., Yu, W. H., Grace, P. S., Schoen, M. K., Tafesse, F., Martin, C., Leung, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.072 · Cited by 571
“…(NK) cells and complement; clearance of target cells by monocytes, neutrophils, and dendritic cells (DCs); immune regulation in inflammation; toxin clearance and neutralization; and antigen presentation by DCs to promote adaptive immunity (Ackerman and Alter, 2013; Nimmerjahn and Ravetch, 2008).”
BackgroundIdentification of a receptor required for the anti-inflammatory activity of IVIG
Anthony, R. M., Wermeling, F., Karlsson, M. C. I., & Ravetch, J. V. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810163105 · Cited by 547
Self-citationFcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications
Smith, K. G. C., & Clatworthy, M. R. (2010) · Nature Reviews Immunology · doi:10.1038/nri2762 · Cited by 543
“Most FcγRs are activating receptors and include the high-affinity receptor FcγRI and a family of low affinity receptors, including FcγRIIA , FcγRIIC , FcγRIIIA and FcγRIIIB in humans, and FcγRIII and FcγRIV in mic”
Niewiesk, S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00446 · Cited by 529
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521
Pučić, M., Knežević, A., Vidič, J., Adamczyk, B., Novokmet, M., Polašek, O., Gornik, O., Šupraha-Goreta, S., Wormald, M. R., Redžić, I., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.010090 · Cited by 524
Type I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B.-M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 514
Self-citationCribbs, D. H., Berchtold, N. C., Perreau, V., Coleman, P. D., Rogers, J., Tenner, A. J., & Cotman, C. W. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-179 · Cited by 499
“FcRs are upregulated in response to innate immune activation, and are increasingly recognized for their contributions to the pathogenesis of neurological disorders [82-84].”
BackgroundFc‐fusion proteins: new developments and future perspectives
Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201379 · Cited by 476
“The attached Fc domain also enables these molecules to interact with Fc-receptors (FcRs) found on immune cells, a feature that is particularly important for their use in oncological therapies and vaccines (Nimmerjahn & Ravetch, 2008).”
Complement receptor 2/CD21− human naive B cells contain mostly autoreactive unresponsive clones
Isnardi, I., Ng, Y.-S., Menard, L., Meyers, G., Saadoun, D., Srdanovic, I., Samuels, J., Berman, J., Buckner, J. H., Cunningham-Rundles, C., et al. (2010) · Blood · doi:10.1182/blood-2009-09-243071 · Cited by 477
Karsten, C. M., Pandey, M. K., Figge, J., Kilchenstein, R., Taylor, P. R., Rosas, M., McDonald, J. U., Orr, S. J., Berger, M., Petzold, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2862 · Cited by 479
Self-citationBroadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
“The common chain cofactor is required for assembly and membrane expression of the activating FcRs I, III, and IV (Nimmerjahn and Ravetch, 2008).”
BackgroundInfluentialKinase inhibition in autoimmunity and inflammation
Zarrin, A. A., Bao, K., Lupardus, P., & Vucic, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0082-8 · Cited by 431
Spatiotemporal immune zonation of the human kidney
Stewart, B. J., Ferdinand, J. R., Young, M. D., Mitchell, T. J., Loudon, K. W., Riding, A. M., Richoz, N., Frazer, G. L., Staniforth, J. U. L., Vieira Braga, F. A., et al. (2019) · Science · doi:10.1126/science.aat5031 · Cited by 426
Halstead, S. B., Mahalingam, S., Marovich, M. A., Ubol, S., & Mosser, D. M. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70166-3 · Cited by 409
Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy
Ram, S., Lewis, L. A., & Rice, P. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00048-09 · Cited by 405
Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis
Matlung, H. L., Babes, L., Zhao, X. W., van Houdt, M., Treffers, L. W., van Rees, D. J., Franke, K., Schornagel, K., Verkuijlen, P., Janssen, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.082 · Cited by 403
Immunoglobulin G glycosylation in aging and diseases
Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 408
Halper-Stromberg, A., Lu, C.-L., Klein, F., Horwitz, J. A., Bournazos, S., Nogueira, L., Eisenreich, T. R., Liu, C., Gazumyan, A., Schaefer, U., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.043 · Cited by 381
“Unlike ART, however, antibodies can engage the host immune system by virtue of their Fc effector domains (Nimmerjahn and Ravetch, 2008) and thereby accelerate clearance of cell-free virus (Igarashi et al.”
Self-citationEnhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S.-Y., Pegu, A., Rudicell, R. S., Yang, Z.-Y., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Rath, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 384
Negative signaling by inhibitory receptors: the NK cell paradigm
Long, E. O. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00660.x · Cited by 370
Basal-like breast cancer: molecular profiles, clinical features and survival outcomes
Milioli, H. H., Tishchenko, I., Riveros, C., Berretta, R., & Moscato, P. (2017) · BMC Medical Genomics · doi:10.1186/s12920-017-0250-9 · Cited by 366
Lauc, G., Huffman, J. E., Pučić, M., Zgaga, L., Adamczyk, B., Mužinić, A., Novokmet, M., Polašek, O., Gornik, O., Krištić, J., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003225 · Cited by 361
“Addition of fucose to the glycan core interferes with the binding of IgG to FccRIIIa and greatly diminishes its capacity for antibody dependent cell-mediated cytotoxicity (ADCC) [13,14].”
BackgroundEradication of spontaneous malignancy by local immunotherapy
Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4488 · Cited by 361
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 354
“The FcγRIIA-131H or FcγRIIIA-158V polymorphisms are associated with a higher affinity for IgG, when compared to their allelic counterparts (92, 93).”
BackgroundIgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
“In contrast, intracellular signaling through the inhibitory FcγRIIb is modulated through the phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which recruit phosphatases that counter-balance activating signaling pathways (Nimmerjahn and Ravetch, 2008).”
BackgroundThe promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
Molecular mechanisms of late apoptotic/necrotic cell clearance
Poon, I. K. H., Hulett, M. D., & Parish, C. R. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.195 · Cited by 354
Gut Microbiota Elicits a Protective Immune Response against Malaria Transmission
Yilmaz, B., Portugal, S., Tran, T. M., Gozzelino, R., Ramos, S., Gomes, J., Regalado, A., Cowan, P. J., d’Apice, A. J. F., Chong, A. S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.053 · Cited by 353
“Complement activation generates C3a and C5a chemoattractants that promote IgG-dependent polymorphonuclear (PMN) cell cytotoxicity (Ding et al., 2008; Nimmerjahn and Ravetch, 2008; Yin et al., 2004).”
BackgroundEnvironmental exposure enhances the internalization of microplastic particles into cells
Ramsperger, A. F. R. M., Narayana, V. K. B., Gross, W., Mohanraj, J., Thelakkat, M., Greiner, A., Schmalz, H., Kress, H., & Laforsch, C. (2020) · Science Advances · doi:10.1126/sciadv.abd1211 · Cited by 347
Programming dendritic cells to induce TH2 and tolerogenic responses
Pulendran, B., Tang, H., & Manicassamy, S. (2010) · Nature Immunology · doi:10.1038/ni.1894 · Cited by 355
“Antigen-antibody complexes can regulate innate and adaptive immune responses through interaction with Fc receptors, which bind to the Fc region of antibodie”
BackgroundFc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
Hogarth, P. M., & Pietersz, G. A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2909 · Cited by 348
Rugo, H. S., Im, S.-A., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., Pegram, M. D., Wright, G. S., Saura, C., Escrivá-de-Romaní, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7932 · Cited by 343
The impact of glycosylation on monoclonal antibody conformation and stability
Zheng, K., Bantog, C., & Bayer, R. (2011) · mAbs · doi:10.4161/mabs.3.6.17922 · Cited by 342
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Di Paolo, J. A., Huang, T., Balazs, M., Barbosa, J., Barck, K. H., Bravo, B. J., Carano, R. A. D., Darrow, J., Davies, D. R., DeForge, L. E., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.481 · Cited by 340
“IgG immune complexes exert their pathogenic effects through activating Fcγ receptors (FcγR), resulting in the initiation of cellular signaling pathways that ultimately trigger inflammatory cytokine production, as well as phagocytic and cytolytic activitie”
BackgroundLi, F., & Ravetch, J. V. (2011) · Science · doi:10.1126/science.1206954 · Cited by 335
Self-citationRecombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Jefferis, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.04.007 · Cited by 330
Circulating and intrahepatic antiviral B cells are defective in hepatitis B
Burton, A. R., Pallett, L. J., McCoy, L. E., Suveizdyte, K., Amin, O. E., Swadling, L., Alberts, E., Davidson, B. R., Kennedy, P. T. F., Gill, U. S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121960 · Cited by 330
Tucsek, Z., Toth, P., Sosnowska, D., Gautam, T., Mitschelen, M., Koller, A., Szalai, G., Sonntag, W. E., Ungvari, Z., & Csiszar, A. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt177 · Cited by 328
Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
West, A. P., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., & Nussenzweig, M. C. (2014) · Cell · doi:10.1016/j.cell.2014.01.052 · Cited by 321
A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs
Anthony, R. M., & Ravetch, J. V. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9405-6 · Cited by 318
“1), where the α1,6 arm sits in the pocket formed in the CH2 domain, and the α1,3 arm projects onto the surface interface of the CH2 and CH3 domains [9, 15].”
BackgroundSelf-citationUniversity of Liverpool - School of Clinical Sciences, U. C. F. T. E. G. F., Bryan, N., Ahswin, H., Smart, N., Bayon, Y., Wohlert, S., & Hunt, J. (2012) · European Cells and Materials · doi:10.22203/ecm.v024a18 · Cited by 318
Modulating IgG effector function by Fc glycan engineering
Li, T., DiLillo, D. J., Bournazos, S., Giddens, J. P., Ravetch, J. V., & Wang, L.-X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702173114 · Cited by 322
Self-citationConceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
Lo, M., Kim, H. S., Tong, R. K., Bainbridge, T. W., Vernes, J.-M., Zhang, Y., Lin, Y. L., Chung, S., Dennis, M. S., Zuchero, Y. J. Y., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767749 · Cited by 323
Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection
Simmons, J. D., Stein, C. M., Seshadri, C., Campo, M., Alter, G., Fortune, S., Schurr, E., Wallis, R. S., Churchyard, G., Mayanja-Kizza, H., et al. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0025-3 · Cited by 314
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 305
Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions
Huang, W., Giddens, J., Fan, S.-Q., Toonstra, C., & Wang, L.-X. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3051266 · Cited by 308
Tissue-mediated control of immunopathology in coeliac disease
Jabri, B., & Sollid, L. M. (2009) · Nature Reviews Immunology · doi:10.1038/nri2670 · Cited by 307
“Furthermore, the formation of immune complexes can trigger activating Fc receptors on APCs, leading to the release of pro-inflammatory mediator”
BackgroundFcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
Pyzik, M., Rath, T., Lencer, W. I., Baker, K., & Blumberg, R. S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403014 · Cited by 298
Human gene expression profiles of susceptibility and resistance in tuberculosis
Maertzdorf, J., Repsilber, D., Parida, S. K., Stanley, K., Roberts, T., Black, G., Walzl, G., & Kaufmann, S. H. E. (2011) · Genes & Immunity · doi:10.1038/gene.2010.51 · Cited by 304
“27 In addition to their antibody binding capacity, the members within the FcγR family comprise a group of molecules that can simultaneously trigger activating and inhibitory signalling pathways to set thresholds for cell activation and thus generate a well-balanced immune response”
BackgroundAdvances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
“— via interaction of the Fc domain with receptors on various cell type”
BackgroundMouse model recapitulating human Fcγ receptor structural and functional diversity
Smith, P., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203954109 · Cited by 307
Self-citationCompromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M. D., Burke, J., Yu, J., Feldman, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.052 · Cited by 297
“Binding was assessed to the FcaR and the low-affinity IgG-FcɣR, the activating FcɣR2A and FcɣR3A receptors, the sole human inhibitory receptor FcɣR2B, and the GPI-anchored FcɣR3B receptor (Nimmerjahn and Ravetch, 2008; Otten and van Egmond, 2004).”
InfluentialB Cells and Humoral Immunity in Atherosclerosis
Tsiantoulas, D., Diehl, C. J., Witztum, J. L., & Binder, C. J. (2014) · Circulation Research · doi:10.1161/circresaha.113.301145 · Cited by 296
MS-Based Allotype-Specific Analysis of Polyclonal IgG-Fc N-Glycosylation
Sénard, T., Gargano, A. F. G., Falck, D., de Taeye, S. W., Rispens, T., Vidarsson, G., Wuhrer, M., Somsen, G. W., & Domínguez-Vega, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02049 · Cited by 292
Targeting B cells and plasma cells in autoimmune diseases
Hofmann, K., Clauder, A.-K., & Manz, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00835 · Cited by 294
Macrophages are critical effectors of antibody therapies for cancer
Weiskopf, K., & Weissman, I. L. (2015) · mAbs · doi:10.1080/19420862.2015.1011450 · Cited by 292
Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology
Sierksma, A., Lu, A., Mancuso, R., Fattorelli, N., Thrupp, N., Salta, E., Zoco, J., Blum, D., Buée, L., De Strooper, B., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910606 · Cited by 291
Inhibiting the C5–C5a receptor axis
Woodruff, T. M., Nandakumar, K. S., & Tedesco, F. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.014 · Cited by 289
“Similar to complement activation, cellular receptors of immunoglobulins (FcRs) play a central role in an immune response (Nimmerjahn and Ravetch, 2008).”
BackgroundEmerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 275
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286
C-reactive protein and inflammation: conformational changes affect function
Wu, Y., Potempa, L. A., El Kebir, D., & Filep, J. G. (2015) · Biological Chemistry · doi:10.1515/hsz-2015-0149 · Cited by 285
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N. S., & Brogdon, J. L. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2014.26 · Cited by 284
Antibody‐mediated modulation of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00910.x · Cited by 285
Self-citationThe immune system and response to HER2-targeted treatment in breast cancer
Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 286
Pierson, T. C., Fremont, D. H., Kuhn, R. J., & Diamond, M. S. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.08.004 · Cited by 281
“Fc-g receptors are expressed on a wide variety of immune cells and belong to a multigene immunoglobulin-like superfamily that can activate or inhibit immune responses depending on their cytoplasmic domain or association with specific signaling molecules (Nimmerjahn and Ravetch, 2008).”
BackgroundIVIG-mediated effector functions in autoimmune and inflammatory diseases
Galeotti, C., Kaveri, S. V., & Bayry, J. (2017) · International Immunology · doi:10.1093/intimm/dxx039 · Cited by 269
“cytoplasmic domain of a single α-chain (1, 2).”
BackgroundImpact of Immune Complex Size and Glycosylation on IgG Binding to Human FcγRs
Lux, A., Yu, X., Scanlan, C. N., & Nimmerjahn, F. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1200501 · Cited by 272
Self-citationVučković, F., Krištić, J., Gudelj, I., Teruel, M., Keser, T., Pezer, M., Pučić‐Baković, M., Štambuk, J., Trbojević‐Akmačić, I., Barrios, C., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39273 · Cited by 269
Lim, S. H., Vaughan, A. T., Ashton-Key, M., Williams, E. L., Dixon, S. V., Chan, H. T. C., Beers, S. A., French, R. R., Cox, K. L., Davies, A. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330357 · Cited by 267
Lowell, C. A. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002352 · Cited by 266
“…pathways often interact indirectly, for example, through the production of cytokines and growth factors and not through direct intracellular biochemical interactions; Hence the term signaling “cross talk,” which now appears commonly in the literature (O’Neill 2008; Ivashkiv 2009; Page et al. 2009).”
BackgroundDifferential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
DiLillo, D. J., & Ravetch, J. V. (2015) · Cell · doi:10.1016/j.cell.2015.04.016 · Cited by 266
“, 2013), while antigen-presenting DCs express a single, distinct low-affinity activating FcgR, hFcgRIIA (Boruchov et al., 2005; Nimmerjahn and Ravetch, 2008).”
InfluentialSelf-citationBehnen, M., Leschczyk, C., Möller, S., Batel, T., Klinger, M., Solbach, W., & Laskay, T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400478 · Cited by 255
“The GPI-linked FcgRIIIB lacks transmembrane and cytoplasmic signaling domains (56) but can”
BackgroundKwissa, M., Nakaya, H. I., Onlamoon, N., Wrammert, J., Villinger, F., Perng, G. C., Yoksan, S., Pattanapanyasat, K., Chokephaibulkit, K., Ahmed, R., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.06.001 · Cited by 254
“Moreover, monocytes are broadly decorated with Fc-γ receptors (Nimmerjahn and Ravetch, 2008; Wong et al., 2011), a recognized feature that contributes to ADE during secondary dengue (Halstead et al., 2010).”
Stanisic, D. I., Richards, J. S., McCallum, F. J., Michon, P., King, C. L., Schoepflin, S., Gilson, P. R., Murphy, V. J., Anders, R. F., Mueller, I., et al. (2009) · Infection and Immunity · doi:10.1128/iai.01129-08 · Cited by 249
IgA subclasses have different effector functions associated with distinct glycosylation profiles
Steffen, U., Koeleman, C. A., Sokolova, M. V., Bang, H., Kleyer, A., Rech, J., Unterweger, H., Schicht, M., Garreis, F., Hahn, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13992-8 · Cited by 263
Metadata
- Authors
- Nimmerjahn, F., & Ravetch, J. V.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Rockefeller University (US)
- Venue
- Nature Reviews Immunology
- Published
- 2008-01
- Volume
- 8
- Issue
- 1
- Pages
- 34-47
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2075901113
- Cited by
- 2,947
- References
- 139
- Citations by year
- 2026: 186 · 2025: 176 · 2024: 158 · 2023: 174 · 2022: 169 · 2021: 196 · 2020: 158 · 2019: 188 · 2018: 151 · 2017: 161 · 2016: 158 · 2015: 170 · 2014: 165 · 2013: 162 · 2012: 181
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- Fc gamma receptor, IgG, antibody subclasses, immune regulation, therapeutic antibodies, autoimmune disease, infectious diseases, cancer immunotherapy, antibody effector functions
- MeSH terms
- Animals, Humans, Immunoglobulin G, Immunity, Receptors, Fc
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.